LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POCT Market Reaches USD 18 Billion in 2016

By LabMedica International staff writers
Posted on 10 Mar 2017
Print article
Sales of point of care (POC) diagnostic testing, both professional testing and self-testing, reached USD 18.4 billion in 2016, driven by emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices that aim to provide expedited diagnosis where the patient is seen or in the patient’s home. These new technologies are allowing POC devices to generate quantitative lab-quality test results and transfer them automatically to an information system, a remote caregiver service for consultation or an electronic medical record.

These are the latest findings of Kalorama Information, an independent medical market research firm.

Over the past 10 years, POC test devices have contributed significantly to the growth of the overall diagnostics market. A large number of diagnostic manufacturers have focused on obtaining CLIA waiver status for their POC devices and CE Mark for POC or self-use. Additionally, more decentralized test venues are investing in non-waived rapid tests and instruments POC testing is expected to play an even more significant role in diagnosis and monitoring patient care.

Currently, molecular POC tests in physician office are available for respiratory infections and more. The market for POC molecular test devices will be driven by their ability to provide precise answers for time sensitive tests, such as sexually transmissible diseases and other infections.

However, with lab budgets across the world being cut for test send-outs, there is a lack of trained technologists to run molecular tests in their present configuration. The new pharma model will resolve this by tailoring therapy to the individual’s particular disease physiology, often determined by the results of a diagnostic test. As a result, more tests – molecular and immunoassays – are expected to come to market, with their adoption being based on performance data, contribution to patient outcome and cost/benefit analysis.

An aging population across the world will provide sufficient room for growth of the POC testing market in the developing as well as developed countries. The evolving POC testing market comprises large and small companies involved in development and/or marketing. The key companies are likely to maintain their leading position in the market through continued product innovation and strategic alliances and mergers.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more